Lower serum vitamin D levels are associated with a higher relapse risk in multiple sclerosis.
OBJECTIVE
There is increasing evidence that vitamin D can be protective against the development of multiple sclerosis (MS), but it may also be beneficial for the clinical course of the disease. Our objective was to prospectively investigate if 25-hydroxy-vitamin D (25-OH-D) levels are associated with exacerbation risk in MS in a study with frequent serum measurements.


METHODS
This was a prospective longitudinal study in 73 patients with relapsing-remitting MS. Blood samples for 25-OH-D measurements were taken every 8 weeks. Associations between 25-OH-D levels and exacerbation rates were assessed using Poisson regression (generalized estimating equations) with the individual serum levels as time-dependent variable.


RESULTS
During follow-up (mean 1.7 years), 58 patients experienced a total of 139 exacerbations. Monthly moving averages of 25-OH-D levels were categorized into low (<50 nmol/L), medium (50-100 nmol/L), and high (>100 nmol/L) levels. Exacerbation risk decreased significantly with higher serum vitamin D levels: respective relative exacerbation rates for the medium and high-level category as compared to the low-level category were 0.7 and 0.5 (p value for trend: p = 0.007). The association between 25-OH-D concentrations and exacerbation rate was log linear without a threshold. With each doubling of the serum 25-OH-D concentration the exacerbation rate decreased by 27% (95% confidence interval 8%-42%, p = 0.008).


CONCLUSIONS
Our finding that higher vitamin D levels are associated with decreased exacerbation risk in relapsing-remitting MS suggests a beneficial effect of vitamin D on disease course in MS. However, the possibility of reverse causality cannot be ruled out completely. Randomized intervention studies are therefore needed to investigate the effect of vitamin D supplementation in MS.
Department of Neurology, MS Centre ErasMS, Erasmus MC, Rotterdam, the Netherlands.
Tessel F
TF
Runia
Wim C J
WC
Hop
Yolanda B
YB
de Rijke
Dragan
D
Buljevac
Rogier Q
RQ
Hintzen
D000293:Adolescent; D000328:Adult; D000465:Algorithms; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007239:Infections / Q000150:complications; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000097:blood* / Q000150:complications / Q000503:physiopathology*; D009460:Neurologic Examination; D017711:Nonlinear Dynamics; D016012:Poisson Distribution; D011446:Prospective Studies; D012008:Recurrence; D012306:Risk; D014807:Vitamin D / Q000031:analogs & derivatives / Q000097:blood*; D044465:White People; D055815:Young Adult
D014807:Vitamin D; C104450:25-hydroxyvitamin D